The phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway is critical for cellular growth and metabolism. Correspondingly, loss of function of PTEN, a negative regulator of PI3K, or activating mutations in AKT1, AKT2 or AKT3 have been found in distinct disorders featuring overgrowth or hypoglycemia. We performed exome sequencing of DNA from unaffected and affected cells from an individual with an unclassified syndrome of congenital progressive segmental overgrowth of fibrous and adipose tissue and bone and identified the cancer-associated mutation encoding p.His1047Leu in PIK3CA, the gene that encodes the p110α catalytic subunit of PI3K, only in affected cells. Sequencing of PIK3CA in ten additional individuals with overlapping syndromes identified either the p.His1047Leu alteration or a second cancer-associated alteration, p.His1047Arg, in nine cases. Affected dermal fibroblasts showed enhanced basal and epidermal growth factor (EGF)-stimulated phosphatidylinositol 3,4,5-trisphosphate (PIP3) generation and concomitant activation of downstream signaling relative to their unaffected counterparts. Our findings characterize a distinct overgrowth syndrome, biochemically demonstrate activation of PI3K signaling and thereby identify a rational therapeutic target.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
NCBI Reference Sequence
The authors thank L. Ivey, J.J. Johnston, V. Tasic, M. Walters and E. Choolun for support and advice. The authors are especially grateful to the subjects who participated in this research study and to the Proteus Syndrome Foundations of the United States and United Kingdom, who have supported and encouraged these individuals and our research efforts. V.E.R.P., S.O., D.B.S., I.B. and R.K.S. were supported by the Wellcome Trust (grants 097721/Z/11/Z, 80952/Z/06/Z, 078986/Z/06/Z, 098051/Z/05/Z and 091551/Z/10/Z), the UK Medical Research Council Centre for Obesity and Related Disorders and the UK National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. L.G.B., M.J.L., J.C.S. and A.M.W. were supported by the Intramural Research Program of the National Human Genome Research Institute. S.R., Q.Z. and M.J.O.W. were supported by the Biotechnology and Biological Sciences Research Council (BBSRC). We are grateful for access to exome sequence data from the CoLaus cohort, which was sequenced as part of a partnership between the Wellcome Trust Sanger Institute, the CoLaus principal investigators and the Quantitative Sciences department of GlaxoSmithKline. S.M.H. is supported by the Manchester NIHR Biomedical Research Centre.
Supplementary Tables 1–3, Supplementary Figures 1 and 2 and Supplementary Note